Viatris (HAM:VIA) FFO


HAM:VIA Viatris Inc HAM:VIA
58 GF Score
Price €14.26
GF Value €9.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Viatris FFO?

FFO (Funds from operations) only applies to REITs.

HAM:VIA
58GF Score
Viatris Inc HAM:VIA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • FFO:
  • GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score

Get the complete analysis for HAM:VIA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.26
Price
€9.77
GF Value